213 related articles for article (PubMed ID: 33022074)
21. Antitumor effects of hyaluronan inhibition in desmoid tumors.
Briggs A; Rosenberg L; Buie JD; Rizvi H; Bertagnolli MM; Cho NL
Carcinogenesis; 2015 Feb; 36(2):272-9. PubMed ID: 25556151
[TBL] [Abstract][Full Text] [Related]
22. Human microRNA expression in sporadic and FAP-associated desmoid tumors and correlation with beta-catenin mutations.
Cavallini A; Rotelli MT; Lippolis C; Piscitelli D; Digennaro R; Covelli C; Carella N; Accetturo M; Altomare DF
Oncotarget; 2017 Jun; 8(26):41866-41875. PubMed ID: 28418912
[TBL] [Abstract][Full Text] [Related]
23. Desmoid tumors: who, when and how to treat?
Mikhael R; Smith M; Tzanis D; Watson S; Miah AB; Bonvalot S
Curr Opin Oncol; 2022 Jul; 34(4):335-341. PubMed ID: 35837705
[TBL] [Abstract][Full Text] [Related]
24. Desmoid-type fibromatosis: Current therapeutic strategies and future perspectives.
Ibrahim R; Assi T; Khoury R; Ngo C; Faron M; Verret B; Lévy A; Honoré C; Hénon C; Le Péchoux C; Bahleda R; Le Cesne A
Cancer Treat Rev; 2024 Feb; 123():102675. PubMed ID: 38159438
[TBL] [Abstract][Full Text] [Related]
25. Surgical management of desmoid tumors of the female pelvis.
Mariani A; Nascimento AG; Webb MJ; Sim FH; Podratz KC
J Am Coll Surg; 2000 Aug; 191(2):175-83. PubMed ID: 10945361
[TBL] [Abstract][Full Text] [Related]
26. Abdominal wall desmoid tumors associated with pregnancy: current concepts.
Johner A; Tiwari P; Zetler P; Wiseman SM
Expert Rev Anticancer Ther; 2009 Nov; 9(11):1675-82. PubMed ID: 19895250
[TBL] [Abstract][Full Text] [Related]
27. The initiation, design, and establishment of the Desmoid Tumor Research Foundation Patient Registry and Natural History Study.
Mercier KA; Walsh DM
Rare Tumors; 2019; 11():2036361319880978. PubMed ID: 31662832
[TBL] [Abstract][Full Text] [Related]
28. Extra-abdominal Desmoid Tumor Mimicking Cervical Spine Schwannoma.
Goldstein A; Hoang S; Miller DC; Mesfin FB
Cureus; 2018 Aug; 10(8):e3145. PubMed ID: 30345202
[TBL] [Abstract][Full Text] [Related]
29. A Metabolomics Pilot Study on Desmoid Tumors and Novel Drug Candidates.
Mercier KA; Al-Jazrawe M; Poon R; Acuff Z; Alman B
Sci Rep; 2018 Jan; 8(1):584. PubMed ID: 29330550
[TBL] [Abstract][Full Text] [Related]
30. Effectiveness of doxorubicin-based and liposomal doxorubicin chemotherapies for patients with extra-abdominal desmoid-type fibromatosis: a systematic review.
Shimizu K; Kawashima H; Kawai A; Yoshida M; Nishida Y
Jpn J Clin Oncol; 2020 Oct; 50(11):1274-1281. PubMed ID: 32700733
[TBL] [Abstract][Full Text] [Related]
31. Characteristics of cultured desmoid cells with different CTNNB1 mutation status.
Hamada S; Urakawa H; Kozawa E; Arai E; Ikuta K; Sakai T; Ishiguro N; Nishida Y
Cancer Med; 2016 Feb; 5(2):352-60. PubMed ID: 26686699
[TBL] [Abstract][Full Text] [Related]
32. [Desmoid-type fibromatosis (aggressive fibromatosis)].
Kuhnen C; Helwing M; Rabstein S; Homann HH; Müller KM
Pathologe; 2005 Mar; 26(2):117-26. PubMed ID: 15657684
[TBL] [Abstract][Full Text] [Related]
33. Progressive Desmoid Tumor: Radiomics Compared With Conventional Response Criteria for Predicting Progression During Systemic Therapy-A Multicenter Study by the French Sarcoma Group.
Crombé A; Kind M; Ray-Coquard I; Isambert N; Chevreau C; André T; Lebbe C; Cesne AL; Bompas E; Piperno-Neumann S; Saada E; Bouhamama A; Blay JY; Italiano A;
AJR Am J Roentgenol; 2020 Dec; 215(6):1539-1548. PubMed ID: 32991215
[No Abstract] [Full Text] [Related]
34. Isolated desmoid tumor of pancreatic tail with cyst formation diagnosed by beta-catenin immunostaining: a rare case report with review of literature.
Rao RN; Agarwal P; Rai P; Kumar B
JOP; 2013 May; 14(3):296-301. PubMed ID: 23669485
[TBL] [Abstract][Full Text] [Related]
35. CTNNB1 45F mutation is a molecular prognosticator of increased postoperative primary desmoid tumor recurrence: an independent, multicenter validation study.
Colombo C; Miceli R; Lazar AJ; Perrone F; Pollock RE; Le Cesne A; Hartgrink HH; Cleton-Jansen AM; Domont J; Bovée JV; Bonvalot S; Lev D; Gronchi A
Cancer; 2013 Oct; 119(20):3696-702. PubMed ID: 23913621
[TBL] [Abstract][Full Text] [Related]
36. Wnt targets genes are not differentially expressed in desmoid tumors bearing different activating β-catenin mutations.
Timbergen MJM; Janssen ML; Verhoef C; Grünhagen DJ; Chibon F; Smid M; Sleijfer S; Wiemer EAC
Eur J Surg Oncol; 2019 Apr; 45(4):691-698. PubMed ID: 30528042
[TBL] [Abstract][Full Text] [Related]
37. Desmoid Tumors: A Review of the Literature and Pharmacologic Management.
Sivanesan E; Gitlin MC
J Pain Palliat Care Pharmacother; 2016 Jun; 30(2):99-105. PubMed ID: 27159399
[TBL] [Abstract][Full Text] [Related]
38. Extra-abdominal desmoid fibromatosis: A review of management, current guidance and unanswered questions.
Eastley N; McCulloch T; Esler C; Hennig I; Fairbairn J; Gronchi A; Ashford R
Eur J Surg Oncol; 2016 Jul; 42(7):1071-83. PubMed ID: 26965303
[TBL] [Abstract][Full Text] [Related]
39. Is mutation analysis of β-catenin useful for the diagnosis of desmoid-type fibromatosis? A systematic review.
Sakai T; Hamada S; Koike H; Shimizu K; Yoshida M; Nishida Y
Jpn J Clin Oncol; 2020 Sep; 50(9):1037-1042. PubMed ID: 32533146
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
